{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:06:38Z","timestamp":1783533998826,"version":"3.55.0"},"reference-count":218,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118214","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:12:45Z","timestamp":1759072365000},"page":"118214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics"],"prefix":"10.1016","volume":"301","author":[{"given":"Shan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-9791","authenticated-orcid":false,"given":"Zhennan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118214_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0092-8674(91)90010-V","article-title":"A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations","volume":"65","author":"Matthews","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118214_bib2","first-page":"1641","article-title":"Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR\/CSF1R family","volume":"6","author":"Rosnet","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118214_bib3","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118214_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118214_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib7","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib8","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/sj.onc.1205332","article-title":"Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain","volume":"21","author":"Kiyoi","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118214_bib9","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/0008-5472.CAN-08-2923","article-title":"FMS-like tyrosine kinase 3\u2013internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro","volume":"69","author":"Von Bubnoff","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib10","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2012-01-403493","article-title":"Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3\/ITD leukemia","volume":"120","author":"Williams","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib11","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/cas.16090","article-title":"BRCC36 associates with FLT3\u2010ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia","volume":"115","author":"Liu","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118214_bib12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/nchembio.2486","article-title":"Inhibition of USP10 induces degradation of oncogenic FLT3","volume":"13","author":"Weisberg","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118214_bib13","doi-asserted-by":"crossref","first-page":"30263","DOI":"10.1074\/jbc.M111.232348","article-title":"c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway","volume":"286","author":"Oshikawa","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/leu.2010.114","article-title":"Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation","volume":"24","author":"Buchwald","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41420-023-01528-5","article-title":"NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.118214_bib16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118214_bib17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/2040620717721459","article-title":"Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis","volume":"8","author":"Gallogly","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejmech.2025.118214_bib19","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118214_bib20","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib21","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118214_bib22","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118214_bib24","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fped.2017.00248","article-title":"Targeting FLT3 signaling in childhood acute myeloid leukemia","volume":"5","author":"Sexauer","year":"2017","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ejmech.2025.118214_bib26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118214_bib27","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/bloodadvances.2023010619","article-title":"A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia","volume":"8","author":"Levis","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2025.118214_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117849","article-title":"Novel water-soluble and highly efficient dual type I\/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3)","volume":"296","author":"Sellmer","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib29","article-title":"Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2025.118214_bib30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1078-0432.CCR-17-1629","article-title":"Concurrent inhibition of pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia Cells through Increased Mcl-1 proteasomal degradation","volume":"24","author":"Kapoor","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib31","doi-asserted-by":"crossref","first-page":"11792","DOI":"10.1021\/acs.jmedchem.3c00245","article-title":"Discovery of 2-aminopyrimidine derivatives as potent dual FLT3\/CHK1 inhibitors with significantly reduced hERG inhibitory activities","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-025-00605-y","article-title":"IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response","volume":"14","author":"Yao","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118214_bib34","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V82.4.1110.1110","article-title":"Human FLT3\/FLK2 gene: cDNA cloning and expression in hematopoietic cells","volume":"82","author":"Rosnet","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0888-7543(91)90270-O","article-title":"Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene","volume":"9","author":"Rosnet","year":"1991","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2025.118214_bib36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118214_bib37","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/MCB.25.9.3690-3703.2005","article-title":"Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases","volume":"25","author":"Schmidt-Arras","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118214_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2011-01-329532","article-title":"Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex","volume":"118","author":"Verstraete","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","article-title":"The structural basis for autoinhibition of FLT3 by the juxtamembrane domain","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118214_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/BMI.S22433","article-title":"Class III receptor tyrosine kinases in acute leukemia \u2013 biological functions and modern laboratory analysis","volume":"10s3","author":"Berenstein","year":"2015","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.ejmech.2025.118214_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104367","article-title":"Targeting FLT3 for treating diseases: FLT3 inhibitors","volume":"30","author":"Rong","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118214_bib42","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.4049\/jimmunol.180.11.7358","article-title":"Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte\/macrophage progenitor stages to maintain cell survival","volume":"180","author":"Kikushige","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118214_bib43","first-page":"1212","article-title":"Expression of the flt3 receptor and its ligand on hematopoietic cells","volume":"9","author":"Brasel","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol.\/Oncol. Clin. N"},{"key":"10.1016\/j.ejmech.2025.118214_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107844","article-title":"Strategies targeting FLT3 beyond the kinase inhibitors","volume":"225","author":"Almatani","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118214_bib46","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117788","article-title":"Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges","volume":"182","author":"Rataj","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118214_bib49","first-page":"6572","article-title":"Mitogenic signalling and substrate specificity of the Flk2\/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells","volume":"13","author":"Dosil","year":"1993","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118214_bib50","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib51","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.onc.1203354","article-title":"Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines","volume":"19","author":"Hayakawa","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118214_bib52","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1084\/jem.192.5.719","article-title":"Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling","volume":"192","author":"Zhang","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118214_bib53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118214_bib54","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1038\/sj.onc.1208957","article-title":"Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant","volume":"24","author":"Ishiko","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118214_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12964-025-02157-4","article-title":"Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6","volume":"23","author":"Zhang","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118214_bib57","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"FLT3: ITDoes matter in leukemia","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib58","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib59","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","article-title":"Impact of FLT3-ITD length on prognosis of acute myeloid leukemia","volume":"104","author":"Liu","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118214_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2025.118214_bib61","article-title":"The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors","volume":"1877","author":"Friedman","year":"2022","journal-title":"BBA-Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118214_bib62","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3724\/abbs.2024112","article-title":"Importance of PTM of FLT3 in acute myeloid leukemia","volume":"56","author":"Liu","year":"2024","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ejmech.2025.118214_bib63","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/cancers12102806","article-title":"Novel approaches to target mutant FLT3 leukaemia","volume":"12","author":"M\u00fcller","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118214_bib64","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood.2021011582","article-title":"Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression","volume":"138","author":"Lv","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib65","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.3390\/cells10112992","article-title":"Modulation of FLT3-ITD localization and targeting of distinct downstream signaling pathways as potential strategies to overcome FLT3-inhibitor resistance","volume":"10","author":"Fleischmann","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118214_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074653","article-title":"Pim-1 Kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication","volume":"8","author":"Natarajan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118214_bib67","doi-asserted-by":"crossref","first-page":"45358","DOI":"10.1074\/jbc.M307933200","article-title":"The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death","volume":"278","author":"Yan","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib68","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.tranon.2018.11.001","article-title":"Inhibition of the STAT5\/Pim kinase axis enhances cytotoxic effects of proteasome inhibitors on FLT3-ITD\u2013positive AML cells by cooperatively Inhibiting the mTORC1\/4EBP1\/S6K\/Mcl-1 pathway","volume":"12","author":"Nogami","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib69","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/sj.onc.1207456","article-title":"FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins","volume":"23","author":"Scheijen","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118214_bib70","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood.2019003538","article-title":"FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia","volume":"135","author":"Long","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41420-023-01317-0","article-title":"The GSK3\u03b2\/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors","volume":"9","author":"Qiu","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.118214_bib72","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2015-11-683581","article-title":"Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6","volume":"127","author":"Uras","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108424","article-title":"Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia","volume":"160","author":"Yang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib74","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1182\/blood-2011-07-365726","article-title":"SRC is a signaling mediator in FLT3-ITD\u2013 but not in FLT3-TKD\u2013positive AML","volume":"119","author":"Leischner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib75","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.leu.2404547","article-title":"Lyn is an important component of the signal transduction pathway specific to FLT3\/ITD and can be a therapeutic target in the treatment of AML with FLT3\/ITD","volume":"21","author":"Okamoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/srep12949","article-title":"Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia","volume":"5","author":"Pillinger","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118214_bib77","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3324\/haematol.2022.280884","article-title":"Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy","volume":"108","author":"Zhang","year":"2022","journal-title":"Haematol"},{"key":"10.1016\/j.ejmech.2025.118214_bib78","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","article-title":"SYK Is a critical regulator of FLT3 in acute myeloid leukemia","volume":"25","author":"Puissant","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118214_bib79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41408-024-01187-4","article-title":"RSK1 dependency in FLT3-ITD acute myeloid leukemia","volume":"14","author":"Kong","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2025.118214_bib80","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/s41375-024-02405-5","article-title":"Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins","volume":"38","author":"Halilovic","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib81","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41419-025-07661-6","article-title":"Targeting oncogenic activation of FLT3\/SREBP\/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids","volume":"16","author":"Yin","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118214_bib82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12964-024-01774-9","article-title":"Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting \u03b2-catenin activity via the PP2A-GSK3\u03b2 axis","volume":"22","author":"Jiang","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118214_bib83","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2018.208843","article-title":"FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways","volume":"104","author":"Wu","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118214_bib84","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/s41375-023-02041-5","article-title":"PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia","volume":"37","author":"Alshamleh","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib85","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2017-12-820035","article-title":"Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition","volume":"131","author":"Gallipoli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib86","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib87","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/s41375-019-0465-1","article-title":"FLT3N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis","volume":"33","author":"Hyrenius-Wittsten","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib88","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.18877","article-title":"Mutation spectrum of FLT3 and significance of non\u2010canonical FLT3 mutations in haematological malignancy","volume":"202","author":"Ge","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2025.118214_bib89","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib90","article-title":"FLT3-TKD in the prognosis of patients with acute myeloid leukemia: a meta-analysis","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib91","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood-2024-201058","article-title":"10 Year follow-up of CALGB 10603\/ratify: midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute myeloid leukemia patients aged 18-60 years","volume":"144","author":"Stone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib93","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118214_bib95","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid eukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib96","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD \u2013mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib98","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.3390\/cancers16234028","article-title":"Salvage therapy with second-generation inhibitors for FLT3 mutated acute myeloid leukemia: a real-world study by the CETLAM and PETHEMA groups","volume":"16","author":"Vives","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118214_bib99","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03445","article-title":"Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy","volume":"3","author":"Warkentin","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118214_bib100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib102","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/leu.2012.67","article-title":"SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants","volume":"26","author":"Cao","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib103","series-title":"A Study of SKLB1028 versus Salvage Chemotherapy in Patients with Relapsed or Refractory (R\/R) AML with FLT3-Mutated (Alive)","year":"2025"},{"key":"10.1016\/j.ejmech.2025.118214_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1239082","article-title":"IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies","volume":"14","author":"Parrondo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118214_bib105","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-190007","article-title":"Preliminary safety and efficacy of emavusertib (CA-4948) in acute myeloid leukemia patients with FLT3 mutation","volume":"142","author":"Winer","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib106","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121954","article-title":"A phase I\/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML","volume":"134","author":"Ciomei","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib108","series-title":"A Study of XY0206 versus Salvage Chemotherapy in Patients with Relapsed or Refractory AML with FLT3-ITD-Mutation (Alive)","year":"2023"},{"key":"10.1016\/j.ejmech.2025.118214_bib109","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/1535-7163.MCT-21-0832","article-title":"Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia","volume":"21","author":"Rice","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118214_bib110","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1182\/blood-2023-181151","article-title":"A phase 1a\/b trial of luxeptinib (CG-806) in patients with relapsed\/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib111","volume":"144","author":"Lin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib112","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2022-165000","article-title":"A potent small molecule inhibitor of FLT3, PHI-101 overcomes resistance in acute myeloid leukemia: efficacy and PK\/PD profile in phase 1 first in human study","volume":"140","author":"Yoon","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib113","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1182\/blood-2022-170445","article-title":"Bmf-500: an orally bioavailable covalent inhibitor of FLT3 with high selectivity and potent antileukemic activity in FLT3-mutated AML","volume":"140","author":"Law","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib114","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6589","article-title":"Covalent-103: a phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL)","volume":"42","author":"Rotta","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib115","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.1021\/acs.jmedchem.4c03023","article-title":"Discovery of FLT3-ITD inhibitor clifutinib: a novel biphenylacetylene urea derivative in clinical trials for the treatment of relapsed\/refractory FLT3-ITD+ acute myeloid leukemia","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114839","article-title":"Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease","volume":"159","author":"Hu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.118214_bib118","article-title":"STI-8591, a novel tyrosine kinase inhibitor, shows excellent antileukemic activity in FLT3-mutated (mut) acute myeloid leukemia (AML)","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib120","author":"Pharma"},{"key":"10.1016\/j.ejmech.2025.118214_bib121","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib122","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13065-023-00981-8","article-title":"Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia","volume":"17","author":"Ezelarab","year":"2023","journal-title":"BMC Chemistry"},{"key":"10.1016\/j.ejmech.2025.118214_bib123","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1182\/blood-2008-09-177030","article-title":"A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response","volume":"113","author":"Pratz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib124","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.0b013e3182074a69","article-title":"Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome","volume":"76","author":"Lehky","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2025.118214_bib126","author":"Akinion Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118214_bib127","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-018-0099-5","article-title":"Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study","volume":"118","author":"Tibes","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118214_bib128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3324\/haematol.2022.281216","article-title":"A phase Ib trial of mivavotinib (TAK-659), a dual SYK\/FLT3 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia","volume":"108","author":"Pratz","year":"2022","journal-title":"Haematol"},{"key":"10.1016\/j.ejmech.2025.118214_bib129","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.118214_bib131","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17460441.2015.1006194","article-title":"The discovery and development of sorafenib for the treatment of thyroid cancer","volume":"10","author":"White","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118214_bib132","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejmech.2025.118214_bib133","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118214_bib134","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.118214_bib135","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk\u2010stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.118214_bib136","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib137","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib138","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/biomedicines10102441","article-title":"Recent advances in the development of anti-FLT3 CAR T-cell therapies for treatment of AML","volume":"10","author":"Pedersen","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118214_bib139","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7032","article-title":"Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy","volume":"37","author":"Karbowski","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib140","author":"Amgen"},{"key":"10.1016\/j.ejmech.2025.118214_bib141","author":"Children\u2019s Hospital"},{"key":"10.1016\/j.ejmech.2025.118214_bib142","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib143","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood-2022-157453","article-title":"Senti-202, a selective, off-the-shelf, preclinical CAR-NK cell therapy with CD33 and\/or FLT3 activating CAR, healthy cell protection from endomucin (EMCN) inhibitory CAR and calibrated release IL-15 for hematologic malignancies including AML","volume":"140","author":"Garrison","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib144","doi-asserted-by":"crossref","unstructured":"M. Muftuoglu, E. Hong, S.A. Strickland, A. Eghtedar, G. Schiller, N. Farhadfar, A.R. Bajel, F. Ravandi, M. Basyal, L. Li, L. Naitmazi, R. Emery, B.S. Garrison, T. Lu, K. Rajangam, M. Andreeff, First-in-human, multicenter study of SENTI-202, a CD33\/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Correlative data, n.d. https:\/\/www.sentibio.com\/wp-content\/uploads\/2025\/04\/AACR-2025-SENTI-202-101-Correlative-Data-Poster.pdf.","DOI":"10.1158\/1538-7445.AM2025-CT143"},{"key":"10.1016\/j.ejmech.2025.118214_bib145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003882","article-title":"A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL","volume":"10","author":"Mehta","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2025.118214_bib146","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-201478","article-title":"A phase 1, open-label, dose escalation and dose expansion study of Cln-049 for the treatment of acute myeloid leukemia patients with measurable residual disease","volume":"144","author":"Heitmann","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib147","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-23-2808","article-title":"Phase I study of GS-3583, an FMS-like tyrosine kinase 3 agonist Fc fusion protein, in patients with advanced solid tumors","volume":"30","author":"Tolcher","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib148","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2559","article-title":"GS-3583, a novel FLT3 agonist Fc fusion protein, to expand conventional dendritic cells in healthy volunteers","volume":"39","author":"Rajakumaraswamy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib149","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-020-00143-y","article-title":"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2025.118214_bib150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/1078-0432.CCR-24-3693","article-title":"Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer","volume":"31","author":"Galsky","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib151","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2697","article-title":"A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors","volume":"42","author":"Ito","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107690","article-title":"Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: a phase 1 study","volume":"152","author":"Al Malki","year":"2025","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106645","article-title":"Design, synthesis, and biological evaluation of a series of indolone derivatives as novel FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"138","author":"Jin","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib154","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/acs.jmedchem.1c01792","article-title":"Identification of 2-aminopyrimidine derivatives as FLT3 kinase inhibitors with high selectivity over c-KIT","volume":"65","author":"Tong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114356","article-title":"Discovery of indirubin-3\u2032-aminooxy-acetamide derivatives as potent and selective FLT3\/D835Y mutant kinase inhibitors for acute myeloid leukemia","volume":"237","author":"Lee","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116539","article-title":"Discovery of a potent CDKs\/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML","volume":"275","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib157","article-title":"Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors","volume":"289","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib158","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1021\/acsmedchemlett.5c00147","article-title":"IRAK1\/4\/pan-FLT3 kinase inhibitors with reduced hERG block as treatments for acute myeloid leukemia","volume":"16","author":"Hoyt","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118214_bib159","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2016.12.038","article-title":"Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)","volume":"127","author":"Ma","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib160","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib161","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118214_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116717","article-title":"FLT3-PROTACs for combating AML resistance: analytical overview on chimeric agents developed, challenges, and future perspectives","volume":"277","author":"Hesham","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib163","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","article-title":"Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib164","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/molecules26051275","article-title":"Evaluation of fused pyrrolothiazole systems as correctors of mutant CFTR protein","volume":"26","author":"Span\u00f2","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118214_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107552","article-title":"An overview on anti-tubulin agents for the treatment of lymphoma patients","volume":"211","author":"Barreca","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118214_bib166","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1021\/acs.jmedchem.6b00777","article-title":"Preclinical activity of new [1,2]Oxazolo[5,4-e]isoindole derivatives in diffuse malignant peritoneal mesothelioma","volume":"59","author":"Span\u00f2","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114292","article-title":"Synthesis of 2H-Imidazo[2\u2032,1\u2019:2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3\/ITD mutations","volume":"235","author":"Cilibrasi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib168","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1021\/acs.jmedchem.1c01215","article-title":"Bioisosteres of the phenyl ring: recent strategic applications in lead optimization and drug design","volume":"64","author":"Subbaiah","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib169","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1021\/jm300042x","article-title":"Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo","volume":"55","author":"Li","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib170","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cmdc.201300571","article-title":"Facile identification of dual FLT3\u2013Aurora A inhibitors: a computer\u2010guided drug design approach","volume":"9","author":"Chang Hsu","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118214_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116962","article-title":"Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors","volume":"280","author":"Moradi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib172","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1039\/C8CC01154K","article-title":"Tetrahydro-3H-pyrazolo[4,3- a]phenanthridine-based CDK inhibitor","volume":"54","author":"Opoku-Temeng","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118214_bib173","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4155\/fmc-2017-0298","article-title":"Dual FLT3\/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines","volume":"10","author":"Dayal","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib174","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118214_bib176","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1021\/acs.jmedchem.1c00330","article-title":"3H-Pyrazolo[4,3-f]quinoline-based kinase inhibitors inhibit the proliferation of acute myeloid leukemia cells in vivo","volume":"64","author":"Dayal","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126630","article-title":"Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"29","author":"Xu","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118214_bib178","article-title":"Discovery of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"283","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216933","article-title":"FLT3-selective PROTAC: enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia","volume":"592","author":"Tan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118214_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107477","article-title":"Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia","volume":"149","author":"Ye","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115974","article-title":"Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia","volume":"264","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib182","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejmech.2012.09.034","article-title":"Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents","volume":"57","author":"Lukasik","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113215","article-title":"Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations","volume":"213","author":"Long","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib184","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1021\/acs.jmedchem.1c02079","article-title":"Identification of the benzoimidazole compound as a selective FLT3 inhibitor by cell-based high-throughput screening of a diversity library","volume":"65","author":"Tian","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib185","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1016\/j.bmc.2018.08.013","article-title":"Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase","volume":"26","author":"Shi","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116937","article-title":"Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia","volume":"70","author":"Kang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib187","doi-asserted-by":"crossref","first-page":"21752","DOI":"10.1021\/acs.jmedchem.4c00529","article-title":"Discovery of SILA-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations","volume":"67","author":"Wei","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2021.130139","article-title":"Pharmacophore-inspired discovery of FLT3 inhibitor from kimchi","volume":"361","author":"Zhu","year":"2021","journal-title":"Food Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114694","article-title":"Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia","volume":"243","author":"Kang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113112","article-title":"Pharmacological properties of indirubin and its derivatives","volume":"151","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118214_bib191","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bmc.2005.08.008","article-title":"Synthesis and structure\u2013activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities","volume":"14","author":"Moon","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib192","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.bmcl.2010.01.039","article-title":"Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells","volume":"20","author":"Choi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118214_bib193","doi-asserted-by":"crossref","first-page":"924","DOI":"10.18632\/oncotarget.23221","article-title":"Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia","volume":"9","author":"Lee","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118214_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112205","article-title":"Discovery of orally active indirubin-3\u2032-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia","volume":"195","author":"Jeong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib195","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s00044-024-03259-3","article-title":"Docking-guided exploration of the anti-flt3 potential of isoindigo derivatives towards potential treatments of acute myeloid leukemia","volume":"33","author":"Sulaibi","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115860","article-title":"Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia","volume":"262","author":"Ko","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib197","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2018.11.063","article-title":"Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation","volume":"163","author":"Heng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib198","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejmech.2019.05.021","article-title":"Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model","volume":"176","author":"Heng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib199","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116237","article-title":"Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations","volume":"268","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116596","article-title":"Discovery of a benzimidazole-based dual FLT3\/TrKA inhibitor targeting acute myeloid leukemia","volume":"56","author":"Dokla","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib202","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.70002","article-title":"Structural optimization and MD simulation study of benzimidazole derivatives as potent mutant FLT3 kinase inhibitors targeting AML","volume":"358","author":"El\u2010Deen","year":"2025","journal-title":"Arch. Pharmazie"},{"key":"10.1016\/j.ejmech.2025.118214_bib203","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1021\/jm058033i","article-title":"Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase","volume":"49","author":"Mahboobi","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112232","article-title":"A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia","volume":"193","author":"Sellmer","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2021.10.011","article-title":"Identification of a highly efficient dual type I\/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells","volume":"29","author":"Beyer","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118214_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129519","article-title":"Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors","volume":"96","author":"Lian","year":"2023","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118214_bib207","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7H -pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N -(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H -pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115448","article-title":"Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor","volume":"256","author":"Zhi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib209","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2013-04-493916","article-title":"G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia","volume":"123","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.130082","article-title":"Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia","volume":"117","author":"Liu","year":"2025","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118214_bib211","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1021\/acsptsci.4c00071","article-title":"Structure-based optimization of pyrazinamide-containing macrocyclic derivatives as Fms-like tyrosine kinase 3 (FLT3) inhibitors to overcome clinical mutations","volume":"7","author":"Zheng","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.118214_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113776","article-title":"Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor","volume":"225","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib213","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115977","article-title":"An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD\/F691L","volume":"264","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib214","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.1021\/acs.jmedchem.3c00575","article-title":"Inhibition of FLT3-ITD kinase in acute myeloid leukemia by new imidazo[1,2-b]pyridazine derivatives identified by scaffold hopping","volume":"66","author":"B\u0159ehov\u00e1","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib215","doi-asserted-by":"crossref","DOI":"10.1002\/jmr.2842","article-title":"Optimization of norbornyl\u2010based carbocyclic nucleoside analogs as cyclin\u2010dependent kinase 2 inhibitors","volume":"33","author":"K\u00f6pr\u00fcl\u00fco\u011flu","year":"2020","journal-title":"J. Mol. Recogn."},{"key":"10.1016\/j.ejmech.2025.118214_bib216","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1074-5521(99)80048-9","article-title":"Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors","volume":"6","author":"Chang","year":"1999","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118214_bib217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.jnatprod.0c00589","article-title":"Investigation of selected flavonoid derivatives as potent FLT3 inhibitors for the potential treatment of acute myeloid leukemia","volume":"84","author":"Yen","year":"2021","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2025.118214_bib218","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/leu.2012.52","article-title":"Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns","volume":"26","author":"Moore","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118214_bib219","doi-asserted-by":"crossref","first-page":"21749","DOI":"10.1021\/acs.jmedchem.4c02878","article-title":"Overcoming resistance to FLT3-ITD therapeutics","volume":"67","author":"McInnes","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118214_bib220","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib221","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118214_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2024.102774","article-title":"Machine learning approaches in predicting allosteric sites","volume":"85","author":"Ner\u00edn-Fonz","year":"2024","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2025.118214_bib223","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib224","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118214_bib225","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-15-2949","article-title":"Eradication of acute myeloid leukemia with FLT3 ligand\u2013targeted miR-150 nanoparticles","volume":"76","author":"Jiang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118214_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.109779","article-title":"Red blood cell membrane-coated FLT3 inhibitor nanoparticles to enhance FLT3-ITD acute myeloid leukemia treatment","volume":"35","author":"Liu","year":"2024","journal-title":"Chin. Chem. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:58:52Z","timestamp":1762675132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":218,"alternative-id":["S0223523425009791"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118214","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118214"}}